Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for belimumab

  1. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.

    Technology appraisal guidance
    Published
    15 December 2021
    View recommendations

    Sections for TA752

  2. Belimumab for treating lupus nephritis (terminated appraisal) (TA806)

    NICE is unable to make a recommendation on belimumab (Benlysta) for treating lupus nephritis. This is because GlaxoSmithKline did not provide an evidence submission.

    Technology appraisal guidance
    Published
    13 July 2022

    Sections for TA806

  3. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.

    Technology appraisal guidance
    Published
    12 February 2026

    Sections for TA1131

  5. Past appeals and decisions

    Past technology appraisal appeals and decisions

  6. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued Reference number: GID-TA10869

    Technology appraisal guidance
    Discontinued

  7. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    This guidance has been updated and replaced by NICE technology appraisal guidance 752.

    Withdrawn guidance